ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
ScripIn the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma? , we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a fe
ScripThe confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and
In VivoAre platforms the new products? That was the question posed during a BIO-Europe Spring panel discussion with industry leaders from prominent platform companies operating across the spectrum of life sc